FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials.
Saved in:
| Title: | FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Selecting Optimized Dosages for Registrational Trials. |
|---|---|
| Authors: | Shord SS; U.S. Food and Drug Administration, Silver Spring, Maryland., Chen C; Merck & Co., Inc., Rahway, New Jersey., Jin JY; Genentech, South San Francisco, California., Van Wart S; Enhanced Pharmacodynamics, Buffalo, New York., Martin SK; Eli Lilly and Company, Indianapolis, Indiana., Davidson BA; American Association for Cancer Research, Washington, District of Columbia., Liu J; U.S. Food and Drug Administration, Silver Spring, Maryland., LoRusso PM; Yale Cancer Center, New Haven, Connecticut., Oxnard GR; Eli Lilly and Company, Indianapolis, Indiana. |
| Source: | Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2025 Dec 01; Vol. 31 (23), pp. 4891-4898. |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9502500 Publication Model: Print Cited Medium: Internet ISSN: 1557-3265 (Electronic) Linking ISSN: 10780432 NLM ISO Abbreviation: Clin Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
